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Abstract: Biosimilar has the advantages of precise efficacy, high safety and stable quality, and occupy an important po-
sition in the field of anti-tumor therapy. In order to reduce the expenditure of drugs, the research and development 
of biosimilar drugs has attracted much attention. Compared with European and American countries in the development 
of the anti-tumor biosimilar industry, there are still some shortcomings and parts that need improvement in China. Ac-
cording to the current development status of China, analyzed the reasons for the development dilemma of my country’s 
anti-tumor biosimilar industry, and put forward suggestions for the development of this industry. 
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1. Development overview 
With the gradual expiration of patent protection 
of biosimilar drugs, the expansion of domestic market 
demand and the development of research and evolution 
technology, the improvement of biosimilar drugs 
has become a hot spot for medical institutions, compa-
nies and cancer patients. In recent years, due to the ac-
curate efficacy of biosimilar, it has played an important 
role in the field of tumor treatment. In the field of tumor 
treatment, the research and development of monoclonal 
antibody biosimilar drugs is in full swing, which is ex-
pected to optimize clinical decision-making and patient 
treatment options in the future
[1]
. Currently, biopharma-
ceuticals are still doing follow-up and imitation research 
in China, and will occupy a leading position in the mar-
ket for a long time in the future
[2]
. Especially in low- and 
middle-income countries, biosimilars have gradual-




2. Existing difficulties 
2.1 Technical problems of production 
equipment 
For biosimilars to be “highly similar” to 
proved biotech drugs, developers must not only use the 
most advanced technology to demonstrate that their 
products are produced with consistent quality stand-
ards, but they must also be sufficiently similar to refer-
ence drugs. This not only places higher requirements on 
the professional competence of researchers, but also has 
corresponding requirements on the advanced nature of 
production equipment and the ability to operate equip-
ment. Although many biosimilar companies in my coun-
try have introduced a large number of production lines  
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with advanced technology in order to improve the effi-
ciency and quality of biosimilars, some companies have 
not established modern operation and management mod-
els, and only position biopharmaceuticals as machinery 
for products. Processing, resulting in increased equip-
ment failure problems. Therefore, technical personnel 
who understand and use advanced production equipment 
are needed to assist. 
2.2 Brand awareness issues 
Because according to the Pharmaceutical Advertis-
ing Management Law some drugs cannot be advertised 
in mass media other than professional journals. Except 
for professionals and those who often pay attention to 
this aspect, they know a little more 
lar brands, and others don’t know much about biosimi-
lar brands. Due to the limited channels for obtaining rel-
evant news, some people do not know how to get the 
latest news. There are also patients who pay less atten-
tion to the brand. For example, one of the an-
ti-tumor biosimilar drugs approved for marketing in 
China is bevacizumab. There are three types of bevaci-
zumab, which are under the three manufacturers of Betta 
Pharmaceuticals, Bio-Thera and Innovent Biologics. The 
patient may know that I want to use bevacizumab, but it 
is not clear which manufacturer it is. 
2.3 Reference listed drug selection problem 
We lack a comprehensive database. At present, there 
are 3 kinds of orange books that are most widely used in 
the world. They are the orange books promulgated by the 
WHO, the US (FDA) and the JPN (PMDA). The Orange 
Book of various countries has clear regulations on refer-
ence listed drug and has established a detailed catalog of 
reference listed drug. In order to better promote the re-
search and development of biosimilars in my country, the 
former China Food and Drug Administration (CFDA) 
issued the Guiding Principles for the Development and 
Evaluation of Biosimilar Drugs (Trial) in March 2015
[4]
. 
In order to standardize the reference listed drug and other 
indicators of generic drugs, my country will officially 
release the China Listed Drug Catalogue similar to the 
Orange Book database on December 29, 2017. Com-
pared with the establishment of databases in other coun-
tries, the consistency evaluation system is still in the 
process of development and growth. 
2.4 The problem of industrial clusters 
As a typical high-tech industry, biopharmaceuticals 
have their own distinctive industrial characteristics. Bi-
opharmaceutical industry has a long industrial chain, 
each node requires professional technology to be realized. 
The closeness of each link of this industry is higher than 
that of other traditional industries and even some 
high-tech industries
[5]
. In 2016–2020 China’s biomedical 
industry cluster development model in-depth analysis 
and development strategy research report, it issued that 
my country has initially formed a fast-growing industrial 
cluster with the Yangtze River Delta and Bohai Rim as 
the core, and the Pearl River Delta, northeast and other 
eastern regions. However, the problem of regional un-
balanced development has also been further revealed. 
For research and development, there is a trend of further 
gathering in Shanghai and Beijing, and accelerating the 
gathering of manufacturing links in Jiangsu and Shan-
dong. Although the overall growth of my country’s bio-
pharmaceutical companies is relatively fast, these com-
panies have problems such as small scale, weak anti-risk 
ability, weak research and development capabilities, and 
single varieties. Most of the same varieties have multiple 
manufacturers, leading to serious homogeneity competi-
tion. For example, some new biomedical companies such 
as Da An Gene and Ke Hua Biology focus on the fields 
of gene kits and blood products, which makes the degree 
of diversification low. Due to the short history of my 
country’s industrial cluster construction, there are still 
shortcomings such as imperfect industrial chain layout 
and blind construction. 
2.5 Talent construction issues 
China has fewer high-level talents in the field of bi-
otechnology drugs. The backwardness of talents will lead 
to backward research and development and prod-
ucts, backward marketing management, etc., which will 
make the domestic pharmaceutical industry complete-
ly backward. This is because the cultivation of biophar-
maceutical talents in my country ranges from junior col-
lege to doctor, with a huge vertical span. Although it 
seems that there are a large number of people study-
ing biopharmaceuticals, due to various reasons such as 
employment situation, job demand and so on, and when 
they arrive at a master’s degree or doctor degree, their 
majors are more refined, which will make the few num-
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ber of people who will eventually study anti-tumor bio-
similar. Compared with European and American coun-
tries, China’s education level still has some differences, 
such as the backwardness of teaching data and the scar-
city of professional equipment. There is also a lack of 
relevant talents engaged in basic research and develop-
ment talents. 
3. Counterplan 
3.1 Establish a talent introduction system 
The development of the industry is inseparable from 
the training and introduction of professional talents. 
Senior professionals are the driving force for the devel-
opment of the anti-tumor biosimilar industry. Under the 
situation of industrial development, focus on the con-
struction of professional teams and strengthen the stand-
ardization and institutionalization of talent introduction. 
Second, build a carrier that is conducive to the growth of 
talents, such as the establishment of new technology 
training bases, and the construction of related scientific 
research workstations to provide a strong growth envi-
ronment for the development of professional talents. 
Furthermore, China’s talent development environment is 
weaker than European and American countries. There-
fore, the country and the governments must implement 
the talent introduction policy and improve the legal sys-
tem that respects knowledge achievements and 
knowledge technology. Attract more high-quality, highly 
sophisticated talents to stay in China. 
3.2 Technological innovation 
A complete and advanced technology in an-
ti-tumor biosimilars is inseparable from academic re-
search and accumulation. China’s research results in this 
area are still relatively lacking. The country can arrange 
for professional and senior talents to go to technologi-
cally powerful countries to exchange and study, broaden 
our knowledge reserves, and improve my country’s 
technological level and innovation capabilities. It also 
needs to strengthen technologies such as large-scale and 
high-throughput gene cloning and protein expression, 
antibody humanization and human antibody preparation, 
new vaccine adjuvants, large-scale cell culture and pro-
tein purification. Innovate in key paths such as biological 
activity, impurity control, stability, toxic and side effects 
control, evaluation methods, and clinical research to de-
velop high-precision biosimilar. 
3.3 Enhance cognitive level 
At present, all anti-tumor biosimilars that have been 
marketed in China are monoclonal antibody biosimilars. 
However, the clinical data of biosimilars before the 
market is limited, and some potential rare or serious 
safety problems have not been fully exposed. The dif-
ferences in immunogenic responses of populations with 
different indications may bring potential safety hazards 
to patients with biosimilar indications
[6]
. Therefore, for 
companies, keep abreast of the latest developments and 
get cutting-edge news in time to improve their core 
competitiveness. For personnel in the medical industry, 
participate in more relevant training to improve their 
awareness. As far as patients and their families are con-
cerned, they usually pay more attention to an-
ti-tumor biosimilar-related news in case of unexpected 
needs. 
3.4 Improve quality standards 
With the introduction of standards for biosimilar, 
the current domestic production standards for an-
ti-tumor biosimilar are mainly based on the Chinese 
Pharmacopoeia (2015 Edition). Most companies aim to 
meet the pharmacopoeial quality requirements, and rare-
ly can in-depth quality analysis. For instance, the purity 
of the product, the immunogenicity of recombinant hu-
man growth hormone and insulin, plenty of crea-
tures believe that it has a great relationship with the im-
purities in the drug. Recombinant human interferon is 
easier to polymerize under certain conditions, and the 
polymerized polymers can produce a more powerful 
immune response, which can directly illustrate the im-
portant connection between active products and impuri-
ties
[7]
. Therefore, my country needs to make further im-
provements under the current quality standards, which is 
very necessary. 
3.5 Strengthen inter-regional communication 
The technical strength, equipment production con-
ditions, and information channels possessed by an enter-
prise are limited. If there is more communication and 
cooperation between enterprises and between regions 
and regions, the effective sharing of resources can be 
realized, and joint efforts will be made to promote the 
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progress of China anti-tumor biosimilar and technology, 
and accelerate the improvement of product quality in this 
industry. Furthermore, the government can strengthen the 
relationship between the government and introduce rele-
vant development plans based on economic and policy 
factors in various regions to jointly guide the develop-
ment of the industry. 
4. Conclusion 
Anti-tumor biosimilars have the advantages of defi-
nite curative effect, high safety and stable quality, and its 
wide clinical application is an inevitable trend. Due to 
the impact of the patent protection of biosimilars, there 
are not many companies that develop biosimilars, and 
technical exchanges in this area are relatively lacking, 
and it is difficult to form specific mature technical stand-
ards. This article analyzes some of the problems of an-
ti-tumor biosimilars in China, and finally puts forward 
some countermeasures from the five perspectives of es-
tablishing a talent introduction system, technological 
innovation, enhancing cognition, improving quality 
standards, and enhancing inter-regional communication. 
Provide assistance in the development and implementa-
tion of biosimilars. I hope that one day in the future, an-
ti-tumor biosimilars can benefit cancer patients and im-
prove their quality of life. 
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